1. Home
  2. ALLO vs ESPR Comparison

ALLO vs ESPR Comparison

Compare ALLO & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALLO
  • ESPR
  • Stock Information
  • Founded
  • ALLO 2017
  • ESPR 2008
  • Country
  • ALLO United States
  • ESPR United States
  • Employees
  • ALLO N/A
  • ESPR N/A
  • Industry
  • ALLO Biotechnology: Biological Products (No Diagnostic Substances)
  • ESPR Biotechnology: Pharmaceutical Preparations
  • Sector
  • ALLO Health Care
  • ESPR Health Care
  • Exchange
  • ALLO Nasdaq
  • ESPR Nasdaq
  • Market Cap
  • ALLO 231.9M
  • ESPR 220.0M
  • IPO Year
  • ALLO 2018
  • ESPR 2013
  • Fundamental
  • Price
  • ALLO $1.05
  • ESPR $2.04
  • Analyst Decision
  • ALLO Strong Buy
  • ESPR Buy
  • Analyst Count
  • ALLO 10
  • ESPR 6
  • Target Price
  • ALLO $8.88
  • ESPR $6.50
  • AVG Volume (30 Days)
  • ALLO 5.8M
  • ESPR 6.8M
  • Earning Date
  • ALLO 08-13-2025
  • ESPR 08-05-2025
  • Dividend Yield
  • ALLO N/A
  • ESPR N/A
  • EPS Growth
  • ALLO N/A
  • ESPR N/A
  • EPS
  • ALLO N/A
  • ESPR N/A
  • Revenue
  • ALLO N/A
  • ESPR $268,125,000.00
  • Revenue This Year
  • ALLO N/A
  • ESPR $6.10
  • Revenue Next Year
  • ALLO $199.63
  • ESPR N/A
  • P/E Ratio
  • ALLO N/A
  • ESPR N/A
  • Revenue Growth
  • ALLO N/A
  • ESPR N/A
  • 52 Week Low
  • ALLO $0.86
  • ESPR $0.69
  • 52 Week High
  • ALLO $3.78
  • ESPR $3.94
  • Technical
  • Relative Strength Index (RSI)
  • ALLO 38.79
  • ESPR 69.62
  • Support Level
  • ALLO $0.99
  • ESPR $2.01
  • Resistance Level
  • ALLO $1.21
  • ESPR $2.19
  • Average True Range (ATR)
  • ALLO 0.10
  • ESPR 0.16
  • MACD
  • ALLO -0.01
  • ESPR 0.03
  • Stochastic Oscillator
  • ALLO 20.59
  • ESPR 82.35

About ALLO Allogene Therapeutics Inc.

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.

About ESPR Esperion Therapeutics Inc.

Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.

Share on Social Networks: